Proximus harnesses ADVA synchronization solution for 5G network timing
23.3.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Proximus is leveraging its Oscilloquartz timing technology to synchronize Belgium’s largest open mobile network. The deployment enables Proximus to improve speed, coverage and reliability for millions of mobile users throughout Belgium, while also preparing its network for next-generation services. By deploying ADVA’s core grandmaster devices, access boundary clocks and its enhanced primary reference time clock (ePRTC) solution, the country’s incumbent telecommunications service provider is ensuring the levels of timing accuracy and resilience needed for 5G, broadcast and other time-sensitive services. The technology was implemented by ADVA’s partner Arcadiz Telecom, a leading provider of connectivity solutions across the Benelux region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005060/en/
ADVA’s timing technology is an integral part of Proximus’s 5G strategy (Photo: Business Wire)
“By harnessing ADVA’s network timing innovation, we’re ensuring unprecedented levels of precision and reliability. This deployment is a core component of our 5G strategy. It means more value not only for our customers looking to access data-intensive applications and stream high-quality video wherever they are, but also for telco operators using our open network,” said Patrick Delcoigne, director, network engineering and operations, Proximus. “ADVA’s grandmaster clock and ePRC cesium technology empower us to meet key timing challenges. It enables highly accurate phase precision, enhanced stability and long-term protection from GNSS outages. Just as important, though, is the support of the ADVA and Arcadiz Telecom team. Their engineers have worked closely with us to ensure that the network meets all of our requirements.”
Proximus’s new nationwide synchronization network is built on the OSA 5440, an ultra-stable timing solution optimized for deployment in core networks and the OSA 5412 family of cost-effective, mid-scale synchronization devices engineered for deployment in a wide range of locations. It’s anchored by the robust and proven OSA 3230B ePRC cesium clock installed in two central sites. This supports high levels of frequency stability compliant with the strictest ITU-T standards and, combined with the OSA 5440, ensures long-term stability of UTC time. The extended stability performance of ADVA’s ePRC provides immunity against GNSS outages – a crucial requirement for mission-critical applications that should not rely on satellite-based timing alone.
“For major mobile network operators like Proximus, our PTP grandmaster and boundary clocks and our ePRTC solution are the perfect tools. They enhance overall performance and deliver the precision timing necessary for 5G use cases. Our technology also enables other services such as broadcast networks to migrate to IP-based timing,” commented Jörg Urban, senior director, business development, Oscilloquartz, ADVA. “The OSA 5412 Series and OSA 5440 support a smooth and cost-effective migration to next-generation phase and frequency synchronization. And with our ePRTC solution providing robust backup for GNSS, Proximus’ mobile customers can be sure of high-quality, uninterrupted services with no loss of performance.”
“At Arcadiz Telecom, we know what it takes to build a network ready to support tomorrow’s services. With ADVA’s Oscilloquartz timing technology and the ongoing support and maintenance of our team, Proximus can be confident that its synchronization infrastructure delivers for today’s needs while being fully equipped for the future,” said Marc Vandeputte, CTO, Arcadiz Telecom. “When it comes to 5G connectivity, every nanosecond counts. That’s why the stringent accuracy and stability of ADVA’s technology is so important. It empowers Proximus to deliver enhanced speeds, coverage and quality to its mobile users. For Belgians, this deployment will enable a wide range of new experiences from instant access to video streams to immersive AR and VR experiences.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005060/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
